What is eGenesis?
Founded in 2015 and headquartered in Cambridge, Massachusetts, eGenesis is at the forefront of developing human transplantable organs, tissues, and cells through advanced gene editing and genome engineering techniques. The company's core mission is to address the critical shortage of donor organs by creating a viable source of transplantable materials derived from genetically modified animals. This innovative approach holds the potential to revolutionize transplant medicine and save countless lives.
How much funding has eGenesis raised?
eGenesis has raised a total of $456M across 5 funding rounds:
Angel/Seed
$2M
Series A
$38M
Series B
$100M
Series C
$125M
Series D
$191M
Angel/Seed (2016): $2M, investors not publicly disclosed
Series A (2017): $38M led by Alexandria Equities, Alta Partners, Biomatics Capital, Khosla Ventures, Heritage Provider Network, and ARCH Venture Partners
Series B (2019): $100M supported by Arch Venture Partners, Wellington Partners, Alta Partners, Biomatics Capital, Khosla Ventures, Fresenius Medical Care Ventures, and Leaps by Bayer
Series C (2021): $125M featuring The Invus Group , LLC, Samsara BioCapital, Farallon Capital Management , L.L.C., Polaris Partners Pte. Ltd, and HBM Healthcare Investments AG
Series D (2024): $191M backed by Lux Capital, Arch Capital, and Khosla Ventures
Key Investors in eGenesis
Lux Capital
Lux Capital is a venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials.
Arch Capital
Arch Capital Group Ltd. is a global financial services company that writes insurance, reinsurance, and mortgage insurance on a worldwide basis, recognized as an S&P 500 company.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on a broad range of areas including consumer, enterprise, AI, fintech, semiconductors, health, agriculture/food, sustainable energy, and robotics.
What's next for eGenesis?
With the recent infusion of capital, eGenesis is poised to accelerate its research and development efforts, scale its manufacturing capabilities, and advance its lead programs towards clinical trials. The company's strategic focus on overcoming immunological barriers and ensuring the safety and efficacy of xenotransplantation is expected to drive significant progress. This major strategic investment signals strong confidence from investors in eGenesis's technology and its potential to disrupt the organ transplant market, paving the way for a new era in regenerative medicine.
See full eGenesis company page
